Clinical characteristics of EGFR-ctDNA shedders in EGFR-mutant NSCLC patients
Background: Circulating tumor DNA (ctDNA) revolutionized the molecular diagnostics of lung cancer by enabling non-invasive, sensitive identification of actionable mutations. However, ctDNA analysis may be challenging due to tumor shedding variability, leading to false negative results. This study ai...
Saved in:
Main Authors: | Martina Ruglioni, Iacopo Petrini, Stefania Crucitta, Andrea Sbrana, Giovanna Irene Luculli, Leila Sadeghi Gol, Carola Forte, Antonio Chella, Christian Rolfo, Romano Danesi, Marzia Del Re |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2025-02-01
|
Series: | Translational Oncology |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1936523324003541 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR-mutated NSCLC: a network meta-analysis
by: Ao Liu, et al.
Published: (2024-11-01) -
Correction: EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR-mutated NSCLC: a network meta-analysis
by: Ao Liu, et al.
Published: (2025-01-01) -
Monitoring of Circulating Tumor DNA and Indication of De-Escalation Adjuvant Targeted Therapy for EGFR-Mutated NSCLC After Complete Resection
by: Song Dong, PhD, et al.
Published: (2025-01-01) -
Elucidating the potential of EGFR mutated NSCLC and identifying its multitargeted inhibitors
by: Anakha D. Rajeeve, et al.
Published: (2025-01-01) -
Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR‐mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis
by: Shang‐Gin Wu, et al.
Published: (2025-01-01)